REDECT

Renal Masses: Pivotal Trial To Detect clear-cell RCC with pre-surgical PET/CT. REDECT is a Phase III trial, which will evaluate whether imaging with REDECTANE® can improve the diagnosis in comparison to the current standard (CT)

Seite gelesen: 919 | Heute: 5
Seite gelesen: 920 | Heute: 6